In 2017, the WHO took the critical steps of acknowledging the need for/impact of adherence interventions and approving certain evidence-based adherence technologies for use with DS-TB patients. In 2018, the Stop TB Partnership, through its TB REACH initiative, has selected and will soon be funding 14 projects demonstrating the feasibility, acceptability, and health outcomes impact of these adherence technologies across a wide range of high burden regions. Finally, and most recently, Unitaid proposes to take the further evaluation and use of these adherence technologies to real scale, soliciting “proposals that could demonstrate the feasibility of using innovative adherence technologies at scale to improve outcomes . . . in supporting MDR-TB treatment, as well as drug-susceptible and preventive treatment.” Final proposals are later this month, however early indications are that there is significant interest and engagement by a wide range of approved technology providers, NGOs/implementation partners, and country programs. As we said, momentum building — and we’re proud to have been a part of it!